Annual Total Liabilities
$153.57 M
+$78.02 M+103.25%
December 31, 2021
Summary
- As of February 10, 2025, PHAS annual total liabilities is $153.57 million, with the most recent change of +$78.02 million (+103.25%) on December 31, 2021.
- During the last 3 years, PHAS annual total liabilities has risen by +$141.47 million (+1169.31%).
Performance
PHAS Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Total Liabilities
$139.56 M
-$1.50 M-1.06%
June 30, 2022
Summary
- As of February 10, 2025, PHAS quarterly total liabilities is $139.56 million, with the most recent change of -$1.50 million (-1.06%) on June 30, 2022.
- Over the past year, PHAS quarterly total liabilities has increased by +$19.75 million (+16.49%).
Performance
PHAS Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PHAS Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +103.3% | +16.5% |
| 3 y3 years | +1169.3% | +781.7% |
| 5 y5 years | +37.7% | - |
PHAS Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -9.1% | at low |
| 5 y | 5-year | at high | -85.3% | -9.1% | -83.9% |
| alltime | all time | at high | -92.1% | -9.1% | -93.4% |
PhaseBio Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $139.56 M(-1.1%) |
| Mar 2022 | - | $141.06 M(-8.1%) |
| Dec 2021 | $153.57 M(+103.3%) | $153.57 M(+19.9%) |
| Sep 2021 | - | $128.05 M(+6.9%) |
| Jun 2021 | - | $119.81 M(+29.7%) |
| Mar 2021 | - | $92.41 M(+22.3%) |
| Dec 2020 | $75.56 M | $75.56 M(+40.3%) |
| Sep 2020 | - | $53.85 M(+21.2%) |
| Jun 2020 | - | $44.42 M(+90.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $23.37 M(+3.8%) |
| Dec 2019 | $22.52 M(+86.1%) | $22.52 M(+46.2%) |
| Sep 2019 | - | $15.40 M(-2.7%) |
| Jun 2019 | - | $15.83 M(+28.6%) |
| Mar 2019 | - | $12.30 M(+1.7%) |
| Dec 2018 | $12.10 M(-89.2%) | $12.10 M(-91.6%) |
| Sep 2018 | - | $143.66 M(+1453.6%) |
| Jun 2018 | - | $9.25 M(-91.7%) |
| Dec 2017 | $111.52 M(+22.1%) | $111.52 M |
| Dec 2016 | $91.30 M | - |
FAQ
- What is PhaseBio Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals annual total liabilities year-on-year change?
- What is PhaseBio Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for PhaseBio Pharmaceuticals?
- What is PhaseBio Pharmaceuticals quarterly total liabilities year-on-year change?
What is PhaseBio Pharmaceuticals annual total liabilities?
The current annual total liabilities of PHAS is $153.57 M
What is the all time high annual total liabilities for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high annual total liabilities is $153.57 M
What is PhaseBio Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, PHAS annual total liabilities has changed by +$78.02 M (+103.25%)
What is PhaseBio Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of PHAS is $139.56 M
What is the all time high quarterly total liabilities for PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals all-time high quarterly total liabilities is $153.57 M
What is PhaseBio Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, PHAS quarterly total liabilities has changed by +$19.75 M (+16.49%)